Comparative effectiveness of second-line targeted therapies for metastatic renal cell carcinoma: synthesis of findings from two multi-practice chart reviews in the United States

References

• Howlader N, Noone A, Krapcho M, et al., eds. Cancer of the Kidney and Renal Pelvis – SEER Stat Fact Sheets. SEER Cancer Statistics Review, 1975–2010. 2010. Available at: http://seer.cancer.gov/statfacts/html/kidrp.html [Last accessed 25 June 2013]
   Google Scholar
• National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer, version 1.2013. Fort Washington, PA: National Comprehensive Cancer Network, 2013:1-35. Available at: http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf [Last accessed 21 May 2013]
   Google Scholar
• Oudard S, George D, Medioni J, Motzer R. Treatment options in renal cell carcinoma: past, present and future. Ann Oncol 2007;18(Suppl 10):x25-31
   PubMed Web of Science ®Google Scholar
• Chin AIA, Lam JJSJ, Figlin RARRA, Belldegrun AAS. Surveillance strategies for renal cell carcinoma patients following nephrectomy. Rev Urol 2006;8:1-7
   PubMedGoogle Scholar
• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Renal Cell Cancer Treatment (PDQ®) – Stage IV and Recurrent Renal Cell Cancer. Cancer.gov. 2013:1-8. Available at: http://www.cancer.gov/cancertopics/pdq/treatment/renalcell/HealthProfessional/page8 [Last accessed 24 June 2013]
   Google Scholar
• Iacovelli R, Cartenì G, Sternberg CN, et al. Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: results from a large patient cohort. Eur J Cancer 2013;49:2134-42
   PubMed Web of Science ®Google Scholar
• Escudier B, Goupil MG, Massard C, Fizazi K. Sequential therapy in renal cell carcinoma. Cancer 2009;115(10 Suppl):2321-6
   PubMed Web of Science ®Google Scholar
• Levy A, Menard J, Albiges L, et al. Second line treatment of metastatic renal cell carcinoma: the Institut Gustave Roussy experience with targeted therapies in 251 consecutive patients. Eur J Cancer 2013;49:1898-904
   PubMed Web of Science ®Google Scholar
• Sun M, Lughezzani G, Perrotte P, Karakiewicz PI. Treatment of metastatic renal cell carcinoma. Nat Rev Urol 2010;7:327-38
   PubMed Web of Science ®Google Scholar
• Iacovelli R, Palazzo A, Trenta P, et al. Management of metastatic renal cell carcinoma progressed after sunitinib or another antiangiogenic treatment. Am J Clin Oncol 2013: published online 5 February, 2013, doi:10.1097/COC.0b013e31827de888
   Google Scholar
• Escudier B, Albiges L, Sonpavde G. Optimal management of metastatic renal cell carcinoma: current status. Drugs 2013;73:427-38
   PubMed Web of Science ®Google Scholar
• Clark PE. The role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapy. Kidney Int 2009;76:939-45
   PubMed Web of Science ®Google Scholar
• Audenet F, Yates DR, Cancel-Tassin G, et al. Genetic pathways involved in carcinogenesis of clear cell renal cell carcinoma: genomics towards personalized medicine. BJU Int 2012;109:1864-70
   PubMed Web of Science ®Google Scholar
• Heldwein FL, Escudier B, Smyth G, et al. Metastatic renal cell carcinoma management. Int Braz J Urol 2009;35:256-70
   PubMed Web of Science ®Google Scholar
• Oudard S, Elaidi R-T. Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: optimizing patient benefit. Cancer Treat Rev 2012;38:981-7
   PubMed Web of Science ®Google Scholar
• Ljungberg B, Cowan NC, Hanbury DC, et al. EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 2010;58:398-406
   PubMed Web of Science ®Google Scholar
• Ljungberg B, Bensalah K, Bex A, et al. Guidelines on renal cell carcinoma. European Association of Urology, 2013:1-56. Available at: http://www.uroweb.org/gls/pdf/10_Renal_Cell_Carcinoma_LR.pdf [Last accessed 13 May 2014]
   Google Scholar
• Pfizer Limited. Torisel (Temsirolimus) – Summary of Product Characteristics. European Medicines Agency (EMA), 2007:1-43. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000799/WC500039912.pdf [Last accessed 12 May 2014]
   Google Scholar
• Larkin J, Paine A, Tumur I, et al. Second-line treatments for the management of advanced renal cell carcinoma: systematic review and meta-analysis. Expert Opin Pharmacother 2013;14:27-39
   PubMed Web of Science ®Google Scholar
• Felici A, Bria E, Tortora G, et al. Sequential therapy in metastatic clear cell renal carcinoma: TKI–TKI vs TKI–mTOR. Expert Rev Anticancer Ther 2012;12:1545-57
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Tomczak P, et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol 2013;14:552-62
   PubMed Web of Science ®Google Scholar
• Busch J, Seidel C, Kempkensteffen C, et al. Sequence therapy in patients with metastatic renal cell carcinoma: comparison of common targeted treatment options following failure of receptor tyrosine kinase inhibitors. Eur Urol 2011;60:1163-70
   PubMed Web of Science ®Google Scholar
• Park K, Lee J-L, Park I, et al. Comparative efficacy of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitor as second-line therapy in patients with metastatic renal cell carcinoma after the failure of first-line VE. Med Oncol 2012;29:3291-7
   PubMed Web of Science ®Google Scholar
• Al-Marrawi MY, Rini BI, Harshman LC, et al. The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients. Target Oncol 2013;8:203-9
   PubMed Web of Science ®Google Scholar
• Yang H, Wong MKK, Signorovitch JE, et al. Overall and progression-free survival with everolimus, temsirolimus, or sorafenib as second targeted therapies for metastatic renal cell carcinoma: A retrospective U.S. chart review. J Clin Oncol 2012;30(Suppl):abstr 4612
   Google Scholar
• Wong MK, Yang H, Signorovitch JE, et al. Comparative outcomes of everolimus, temsirolimus and sorafenib as second targeted therapies for metastatic renal cell carcinoma: a US medical record review. Curr Med Res Opin 2014;30:537-45
   PubMed Web of Science ®Google Scholar
• Heng DY, Mackenzie MJ, Vaishampayan UN, et al. Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy. Ann Oncol 2012;23:1549-55
   PubMed Web of Science ®Google Scholar
• Chen C-C, Hess GP, Liu Z, et al. Second-line treatment outcomes after first-line sunitinib therapy in metastatic renal cell carcinoma. Clin Genitourin Cancer 2012;10(4):256-61
   Google Scholar
• Heng DYC, Lee J, Harshman LC, et al. A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma (mRCC). J Clin Oncol 2012;30(suppl 5):abstr 387
   Google Scholar
• Vickers MM, Choueiri TK, Rogers M, et al. Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy. Urology 2010;76:430-4
   PubMed Web of Science ®Google Scholar
• Pasini F, Fraccon AP, Barile C, et al. Targeted therapies (TT) in metastatic renal cell carcinoma (mRCC): an Italian survey of 902 pts. J Clin Oncol 2013;31(Suppl):abstr e15514
   Google Scholar
• Busch J, Seidel C, Erber B, et al. Retrospective comparison of triple-sequence therapies in metastatic renal cell carcinoma. Eur Urol 2013;64:62-70
   PubMed Web of Science ®Google Scholar
• Iacovelli R, Cartenì G, Milella M, et al. Clinical outcomes in patients with metastatic renal cell carcinoma receiving everolimus or temsirolimus after sunitinib. Can Urol Assoc J 2014;8:E121-5
   PubMed Web of Science ®Google Scholar
• Hutson TE, Escudier B, Esteban E, et al. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 2014;32:760-7
   PubMed Web of Science ®Google Scholar
• Soulières D. Side-effects associated with targeted therapies in renal cell carcinoma. Curr Opin Support Palliat Care 2013;7:254-7
   PubMed Web of Science ®Google Scholar
• Atkinson BJ, Cauley DH, Ng C, et al. Mammalian target of rapamycin (mTOR) inhibitor-associated non-infectious pneumonitis in patients with renal cell cancer: predictors, management, and outcomes. BJU Int 2014;113:376-82
   PubMed Web of Science ®Google Scholar